A prospective study in the evaluation of quality of life after vulvar cancer surgery.

Int J Gynecol Cancer

*Department of Obstetrics and Gynecology, 2nd Faculty of Medicine of the Charles University in Prague and Faculty Hospital Motol; and †Faculty of Informatics and Statistics, University of Economics, Prague, Czech Republic.

Published: January 2015

Objective: The aim of this study was to prospectively monitor the patients' quality of life (QoL) after vulvar cancer surgery.

Design: The design was prospective clinical study.

Setting: The study was set in the Department of Obstetrics and Gynecology, 2nd Medical Faculty of the Charles University and University Hospital Motol, Prague, Czech Republic.

Methods: A group of 36 patients underwent vulvar cancer surgery: 24 patients were subject to inguinofemoral lymphadenectomy (RAD) and 12 to sentinel lymph node biopsy. To evaluate QoL, the European Organisation for Research and Treatment of Cancer, QoL questionnaires (QLQ-C30 and QLQ-CX24) were administered to patients before and 6 and 12 months after surgery.

Results: In patients with vulvar cancer after inguinofemoral lymphadenectomy, increased fatigue and impaired lymphedema were observed. In the group of patients after sentinel lymph node biopsy, none of the QoL variables worsened postoperatively. Comparing both groups 12 months after surgery, the RAD group had significantly worse outcomes in body image and cognitive functioning than the sentinel lymph node biopsy group.Patients in the RAD group, who received adjuvant radiotherapy (n = 13), had worse QoL in symptom experience (P < 0.05) at 6 and 12 months after the surgery than patients without radiotherapy (n = 11).

Conclusions: Less radical surgery showed objectively better QoL results.

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000313DOI Listing

Publication Analysis

Top Keywords

vulvar cancer
16
sentinel lymph
12
lymph node
12
node biopsy
12
quality life
8
cancer surgery
8
group patients
8
surgery patients
8
inguinofemoral lymphadenectomy
8
months surgery
8

Similar Publications

Organoid development and applications in gynecological cancers: the new stage of tumor treatment.

J Nanobiotechnology

January 2025

Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, 110004, Liaoning, China.

Gynecologic cancers (GCs), including cervical cancer (CC), ovarian cancer (OC), endometrial cancer (EC), as well as vulvar and vaginal cancers, represent major health threats to women, with increasing incidence rates observed globally. Conventional treatments, such as surgery, radiation therapy, and chemotherapy, are often hindered by challenges such as drug resistance and recurrence, contributing to high mortality rates. Organoid technology has emerged as a transformative tool in cancer research, offering in vitro models that closely replicate the tumor cell architecture and heterogeneity of primary cancers.

View Article and Find Full Text PDF

Current status of fertility preservation procedures in gynecologic oncology: from a Chinese perspective.

J Assist Reprod Genet

January 2025

Department of Gynaecology, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Liaoning Province, Shenyang, 110001, The People's Republic of China.

Background: The "Healthy China" initiative, along with advancements in technology for cancer diagnosis and treatment, has significantly enhanced outcomes for patients with gynecologic tumors. The trends of late marriage and delayed childbirth have led to an increasing number of women diagnosed with gynecologic cancers who are seeking fertility preservation in China. This issue is critical yet often overlooked in clinical practice.

View Article and Find Full Text PDF

Cystic Basal Cell Carcinoma with a Giant Vulvar Cyst.

Acta Dermatovenerol Croat

November 2024

Takayuki Suyama, MD, PhD, Department of Dermatology, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minami-koshigaya, Koshigaya, Saitama, 343-8555, Japan; ORCID ID: 0000-0002-6986-411X.

Cystic basal cell carcinoma (BCC) is a rare subtype of BCC (1). Histologically, it is usually characterized by multiple small cysts without a clinical cystic appearance (2). Herein, we report an unusual case of cystic BCC with a large vulvar cyst.

View Article and Find Full Text PDF

PD-L1-Expression in in primary and recurrent vulvar squamous cell cancer.

Gynecol Oncol

January 2025

Institute of Pathology, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), Friedrich-Alexander-Universität Erlangen-Nürnberg, Krankenhausstrasse 8-10, 91054 Erlangen, Germany.

Background: Squamous cell vulvar carcinoma is a rare malignant disease of women. In higher tumor stages survival rates are poor. Therapy options are limited.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!